Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31436712 | 0.88 | P2RY2 (0.42) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL6514797 | 0.86 | SLC29A1 (0.52) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL882474 | 0.86 | SLC28A1 (0.54) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL6516203 | 0.85 | SLC29A1 (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL766638 | 0.85 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL766413 | 0.85 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL766412 | 0.85 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL766639 | 0.85 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL38661234 | 0.85 | P2RY2 (0.64) | P2RY2P2RY4POLA1P2RY14P2RY6 | |
| SCHEMBL30777693 | 0.85 | P2RY2 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121380249-B | Method for preparing 2' -methoxy-uridine triphosphate | 泰兴合全药业有限公司 | 2026-05-15 | — | — | CN | claimed |
| EP-4683645-A1 | COMPOSITIONS AND METHODS FOR IMPROVED GENE SILENCING | Atalanta Therapeutics, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-12351598-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | Tallac Therapeutics, Inc. (US) | 2025-07-08 | — | — | US | claimed |
| EP-4526449-A2 | SIRNA MOLECULE AGAINST HUMAN TENASCIN-C (TNC) AND A PHARMACEUTICAL COMPOSITION COMPRISING IT | Medicofarma Biotech SA (PL) | 2025-03-26 | — | — | EP | claimed |
| US-20240360445-A1 | CANCER TREATMENT USING siRNA TO MODULATE EXPRESSION OF PRDM2/RIZ PROTEIN | ARIZ PRECISION MEDICINE, INC. | 2024-10-31 | — | — | US | claimed |
| WO-2024197280-A1 | COMPOSITIONS AND METHODS FOR IMPROVED GENE SILENCING | ATALANTA THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| CN-118566493-A | Preparation method of blood reference product applied to next generation metabonomics | 上海阿趣生物科技有限公司 | 2024-08-30 | — | — | CN | claimed |
| WO-2024151745-A2 | TARGETED ANTI-PRDM COMPOSITIONS AND USES THEREOF | ARIZ PRECISION MEDICINE, INC. (US) | 2024-07-18 | — | — | WO | claimed |
| US-12012597-B2 | Cancer treatment using siRNA to modulate expression of PRDM2/RIZ protein | ARIZ PRECISION MEDICINE, INC. (US) | 2024-06-18 | — | — | US | claimed |
| WO-2023224499-A2 | SIRNA MOLECULE AGAINST HUMAN TENASCIN-C (TNC) AND A PHARMACEUTICAL COMPOSITION COMPRISING IT | MEDICOFARMA BIOTECH SA (PL) | 2023-11-23 | — | — | WO | claimed |
| US-20020151072-A1 | Chimeric mutational vectors | VALIGEN (U.S), INC. | 2002-10-17 | — | — | US | claimed |
| EP-1078097-A4 | CELL-FREE CHIMERAPLASTY AND EUKARYOTIC USE OF HETERODUPLEX MUTATIONAL VECTORS | KIMERAGEN INC (US) | 2002-06-05 | — | — | EP | claimed |
| EP-1084272-A4 | HETERODUPLEX MUTATIONAL VECTORS AND USE THEREOF IN BACTERIA | KIMERAGEN INC (US) | 2002-03-13 | — | — | EP | claimed |
| US-6211351-B1 | FOR INTRODUCTION OF GENETIC CHANGES IN EUKARYOTIC CELLS | VALIGEN (US), INC. | 2001-04-03 | — | — | US | claimed |
| EP-1084272-A1 | HETERODUPLEX MUTATIONAL VECTORS AND USE THEREOF IN BACTERIA | Kimeragen Inc. (US) | 2001-03-21 | — | — | EP | claimed |
| EP-1078097-A1 | CELL-FREE CHIMERAPLASTY AND EUKARYOTIC USE OF HETERODUPLEX MUTATIONAL VECTORS | Kimeragen Inc. (US) | 2001-02-28 | — | — | EP | claimed |
| US-6010907-A | TRANSFORMING TARGET DNA SEQUENCES | KIMERAGEN, INC. (US) | 2000-01-04 | — | — | US | claimed |
| US-6004804-A | 3'-EXONUCLEASE PROTECTED DUPLEX MUTATIONAL VECTORS; USED TO MAKE SPECIFIC GENETIC ALTERATIONS IN THE GENOME AND IN PLASMIDS OF TARGET PROKARYOTIC CELLS | KIMERAGEN, INC. (US) | 1999-12-21 | — | — | US | claimed |
| WO-1999058702-A1 | CELL-FREE CHIMERAPLASTY AND EUKARYOTIC USE OF HETERODUPLEX MUTATIONAL VECTORS | KIMERAGEN, INC. (US) | 1999-11-18 | — | — | WO | claimed |
| WO-1999058723-A1 | HETERODUPLEX MUTATIONAL VECTORS AND USE THEREOF IN BACTERIA | KIMERAGEN, INC. (US) | 1999-11-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351598-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TYMP, DUT, PAICS | SLC28A1 516/4885SLC28A2 423/4885SLC29A1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.